ClinicalTrials.gg
RecruitingNCT05993923DIGERUpdated Oct 23, 2026

Impact of a Multidisciplinary Approach in the Perioperative Geriatrics Unit on Functional Status of Patients Aged 70 and Over Operated on for Colorectal Cancer

An interventional study of GPOU in Colorectal Cancer and Surgery, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 4 sites in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.

Planned enrollment
294th of 464
90 · median 152
Started
2023
with 25 others
No phase
116 of 583
25 open now
Primary completion
2028-10
later than 123 of 164 live
Registered
483rd of 583
by date

Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 294th largest by planned enrollment of the 464 interventional ones that give a count, is one of 26 that started in 2023, is one of 116 with no phase, reaches primary completion later than 123 of the 164 other live ones, and was the 483rd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 583 studies in Colorectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

Health establishments encourage the development of specific care pathways for the elderly by supporting Geriatric Peri-Operative Units (GPOU). Indeed, this shared care model has shown a clear reduction in mortality and the number of re-hospitalizations in patients 6 months after their care. The multidisciplinary approach of global management of the patient in the perioperative period aims to reduce surgical stress as well as the rapid restoration of previous physical and psychic abilities. Colorectal surgery, the main treatment for stage I to III colon cancer, is a morbid surgery. Despite numerous efficacy data on improved rehabilitation after colorectal surgery, care programs are not specific to the geriatric population and geriatric assessment criteria to describe the functional status of patients are not commonly used. The study investigators wish to evaluate the impact of GPOU treatment following colorectal surgery, on the evolution of several clinical parameters such as: functional status, morbidity mortality, quality of life, and lifestyle. The study investigators hypothesize that management in the GPOU for colorectal cancer surgery in patients aged 70 and over will improve functional status at 3 months, in comparison with traditional management. The proposed intervention should also lead to an improvement in patient satisfaction with care, complications and re-hospitalizations, nutritional status, lifestyle and patient survival.

03

Conditions studied

  • Colorectal Cancer
  • Surgery

Keywords

  • Elderly
  • Geriatric Unit
  • Postoperative
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient or their representative must have given their free and and signed the consent form
  • The patient must be a member or beneficiary of a health insurance plan
  • Diagnosis of proven colorectal cancer.
  • Patient to benefit from scheduled colorectal surgery at the University Hospital of Nîmes validated in digestive surgery SPC after oncogeriatric evaluation.
  • Surgical act: resection with anastomosis in one step.

Exclusion criteria

Exclusion Criteria:

  • Interventional RIPH patient defined as category 1 if there is interference with the primary endpoint
  • It is impossible to give the subject informed information
  • The patient is under safeguard of justice or state guardianship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • No intervention
    Control group

    Classical management in the digestive surgery department

  • Experimental
    GPOU group

    Treatment is carried out in Peri-Operative Geriatrics Unit to optimize specific geriatric care

    Other: GPOU

Interventions

  • OtherGPOU

    Intervention upstream of the perioperative management according to the nutritional grade. Grade 4 Nutrition patients will be hospitalized earlier, i.e. 10 to 15 days before surgery for the start of artificial nutrition. A temporary return home can be organized with the supervision of a service provider until a second admission for surgical management. Grade 2 Nutrition patients will be called 24 to 48 hours before the surgical procedure. Anticipation of discharge at admittance Early mobilization Comorbidity management Prevention of iatrogenia Management of geriatric frailties Daily medical and paramedical assessment Detailed discharge report

06

What researchers measure

Primary outcomes

  1. Change in functional status after colorectal cancer surgery between groups

    Instrumental Activities of Daily Living (IADL) score (score 0-8)

    Time frame: Baseline and Month 3

Secondary outcomes

  1. Change in functional status between groups

    Instrumental Activities of Daily Living (IADL) score (score 0-8)

    Time frame: Baseline and Month 6

  2. Change in basic functional status between groups

    Katz index of independence in Activities of Daily Living scale (ADL) (score 0-6)

    Time frame: Baseline, hospital discharge (an average of 10 days), Month 3, and Month 6

  3. Change in patient motor ability between groups

    Time Up and Go test (Score 0-3 for each item, time in seconds)

    Time frame: Baseline, Month 3

  4. Patient satisfaction with care between groups

    EORTC SATisfaction with IN-PATient cancer care (IN-PATSAT) 32 questionnaire (Score 32-160)

    Time frame: Hospital discharge (an average of 10 days)

  5. Length of hospital stay between groups

    Days

    Time frame: Hospital discharge (an average of 10 days)

  6. The number of medical complications during hospitalization between groups

    Number of following events: diabetes decompensation, cardiorespiratory decompensation, pulmonary and urinary infections, acute renal failure, anemia. Aggravation of: confusion, pelvic exoneration disorders, fall, bedsores.

    Time frame: Hospital discharge (an average of 10 days)

  7. The distribution of surgical complications between groups

    Gravity of surgical complications according to the Clavien Dindo classification

    Time frame: Hospital discharge (an average of 10 days)

  8. The distribution of surgical complications between groups

    Gravity of surgical complications according to the Clavien Dindo classification

    Time frame: Month 1

  9. Destination of patients on discharge from hospital between groups

    Classified as: home / nursing home or institutionalization / transfer to Aftercare and Rehabilitation / transfer to another service / none (death during hospitalization).

    Time frame: Hospital discharge (an average of 10 days)

  10. The change in the patient's weight between groups

    Percent change in Kg

    Time frame: Baseline and Month 3

  11. Patient quality of life between groups

    EORTC-QLQ-C30 questionnaire score (Score 0-100)

    Time frame: Month 3

  12. Patient quality of life between groups

    EORTC-QLQ-C30 questionnaire score (Score 0-100)

    Time frame: Month 6

  13. Change in the patient's place of abode between groups

    Rate (%) of patients living at home/in nursing home/residential home

    Time frame: Month 1, Month 3 and Month 6

  14. Overall survival between groups.

    Percentage of immediate mortality (during the hospital stay)

    Time frame: Month 1

  15. Overall survival between groups.

    Percentage of immediate mortality (during the hospital stay)

    Time frame: Month 3

  16. Overall survival between groups.

    Percentage of immediate mortality (during the hospital stay)

    Time frame: Month 6

  17. The rate of early unscheduled re-hospitalizations or admissions to the emergency department between groups

    Re-hospitalization in the month following discharge from hospital: yes/no.

    Time frame: Month 1

07

Study locations

3 of 4 sites recruiting
  • Coralie LABARIAS
    Nîmes, France 30029, France
    Recruiting
  • Coralie LABARIAS
    Nîmes, France 30029, France
    Recruiting
  • CHU de Nîmes
    Nîmes, 30029, France
    Recruiting
  • CHU de Nîmes
    Nîmes, France
    Not yet recruiting
    • Anissa Megzari · Contactdrc@chu-nimes.fr · 04.66.68.42.36
    • Coralie Labarias · Principal investigator
    • Martin Bertrand · Sub investigator
    • Luca Theuil · Sub investigator
    • Laetitia GERONIMI ROBELIN · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Oct 2028, 61 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 61 months is above that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2023
First posted
Aug 15, 2023
StartActual
Sep 26, 2023
Primary completionEst.
Oct 30, 2028
CompletionEst.
Oct 30, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05993923
Responsible party
Sponsor
First posted
Aug 15, 2023
Start date
Sep 26, 2023
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Coralie Labarias
Contact
coralie.labarias@chu-nimes.fr
04.66.68.79.46
Coralie Labarias
principal investigator · CHU de Nimes

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion